Skip to main content
Top
Published in: BMC Geriatrics 1/2020

Open Access 01-12-2020 | Research article

Does potentially inappropriate prescribing predict an increased risk of admission to hospital and mortality? A longitudinal study of the ‘oldest old’

Authors: Karen Cardwell, Ngaire Kerse, Carmel M. Hughes, Ruth Teh, Simon A. Moyes, Oliver Menzies, Anna Rolleston, Joanna B. Broad, Cristín Ryan

Published in: BMC Geriatrics | Issue 1/2020

Login to get access

Abstract

Background

Potentially inappropriate prescribing (PIP) is associated with negative health outcomes, including hospitalisation and mortality. Life and Living in Advanced Age: a Cohort Study in New Zealand (LiLACS NZ) is a longitudinal study of Māori (the indigenous population of New Zealand) and non-Māori octogenarians. Health disparities between indigenous and non-indigenous populations are prevalent internationally and engagement of indigenous populations in health research is necessary to understand and address these disparities. Using LiLACS NZ data, this study reports the association of PIP with hospitalisations and mortality prospectively over 36-months follow-up.

Methods

PIP, from pharmacist applied criteria, was reported as potentially inappropriate medicines (PIMs) and potential prescribing omissions (PPOs). The association between PIP and hospitalisations (all-cause, cardiovascular disease-specific and ambulatory-sensitive) and mortality was determined throughout a series of 12-month follow-ups using binary logistic (hospitalisations) and Cox (mortality) regression analysis, reported as odds ratios (ORs) and hazard ratios (HRs), respectively, and the corresponding confidence intervals (CIs).

Results

Full demographic data were obtained for 267 Māori and 404 non-Māori at baseline, 178 Māori and 332 non-Māori at 12-months, and 122 Māori and 281 non-Māori at 24-months. The prevalence of any PIP (i.e. ≥1 PIM and/or PPO) was 66, 75 and 72% for Māori at baseline, 12-months and 24-months, respectively. In non-Māori, the prevalence of any PIP was 62, 71 and 73% at baseline, 12-months and 24-months, respectively. At each time-point, there were more PPOs than PIMs; at baseline Māori were exposed to a significantly greater proportion of PPOs compared to non-Māori (p = 0.02). In Māori: PPOs were associated with a 1.5-fold increase in hospitalisations and mortality. In non-Māori, PIMs were associated with a double risk of mortality.

Conclusions

PIP was associated with an increased risk of hospitalisation and mortality in this cohort. Omissions appear more important for Māori in predicting hospitalisations, and PIMs were more important in non-Māori in predicting mortality. These results suggest understanding prescribing outcomes across and between population groups is needed and emphasises prescribing quality assessment is useful.
Appendix
Available only for authorised users
Literature
1.
go back to reference Moriarty F, Hardy C, Bennett K, Smith SM, Fahey T. Trends and interaction of polypharmacy and potentially inappropriate prescribing in primary care over 15 years in Ireland: a repeated cross-sectional study. BMJ Open. 2015;5:e008656.CrossRef Moriarty F, Hardy C, Bennett K, Smith SM, Fahey T. Trends and interaction of polypharmacy and potentially inappropriate prescribing in primary care over 15 years in Ireland: a repeated cross-sectional study. BMJ Open. 2015;5:e008656.CrossRef
2.
go back to reference Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T, Pirmohamed M, James S, et al. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995–2010. BMC Med. 2015;13:74.CrossRef Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T, Pirmohamed M, James S, et al. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995–2010. BMC Med. 2015;13:74.CrossRef
3.
go back to reference Hill-Taylor B, Sketris I, Hayden J, Byrne S, O’Sullivan D, Christie R. Application of the STOPP/START criteria: a systematic review of the prevalence of potentially inappropriate prescribing in older adults, and evidence of clinical, humanistic and economic impact. J Clin Pharm Ther. 2013;38:360–72.CrossRef Hill-Taylor B, Sketris I, Hayden J, Byrne S, O’Sullivan D, Christie R. Application of the STOPP/START criteria: a systematic review of the prevalence of potentially inappropriate prescribing in older adults, and evidence of clinical, humanistic and economic impact. J Clin Pharm Ther. 2013;38:360–72.CrossRef
4.
go back to reference O’Connor MN, Gallagher P, O’Mahony D. Inappropriate prescribing: criteria, detection and prevention. Drugs Aging. 2012;29:437–52.CrossRef O’Connor MN, Gallagher P, O’Mahony D. Inappropriate prescribing: criteria, detection and prevention. Drugs Aging. 2012;29:437–52.CrossRef
5.
go back to reference American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 Updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63:2227–46.CrossRef American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 Updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63:2227–46.CrossRef
6.
go back to reference Gallagher P, Ryan C, Byrne S, Kennedy J, O’Mahony D. STOPP (Screening Tool of Older Person’s Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus Validation. Int J Clin Pharmacol Ther. 2008;46:72–83.CrossRef Gallagher P, Ryan C, Byrne S, Kennedy J, O’Mahony D. STOPP (Screening Tool of Older Person’s Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus Validation. Int J Clin Pharmacol Ther. 2008;46:72–83.CrossRef
7.
go back to reference O’Mahony D, O’Sullivan D, Byrne S, O’Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44:213–8.CrossRef O’Mahony D, O’Sullivan D, Byrne S, O’Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44:213–8.CrossRef
8.
go back to reference Mangoni AA, Jackson SHD. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2003;57:6–14.CrossRef Mangoni AA, Jackson SHD. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2003;57:6–14.CrossRef
9.
go back to reference Hayman KJ, Kerse N, Dyall L, Kepa M, Teh R, Wham C, et al. Life and Living in Advanced Age: A Cohort Study in New Zealand-Te Puāwaitanga o Nga Tapuwae Kia Ora Tonu. LiLACS NZ: Study protocol. BMC Geriatr. 2012;12:33.PubMed Hayman KJ, Kerse N, Dyall L, Kepa M, Teh R, Wham C, et al. Life and Living in Advanced Age: A Cohort Study in New Zealand-Te Puāwaitanga o Nga Tapuwae Kia Ora Tonu. LiLACS NZ: Study protocol. BMC Geriatr. 2012;12:33.PubMed
10.
go back to reference Jones R, Crowshoe L, Reid P, Calam B, Curtis E, Green M, et al. Educating for Indigenous Health Equity. Acad Med. 2019;94:512–9.CrossRef Jones R, Crowshoe L, Reid P, Calam B, Curtis E, Green M, et al. Educating for Indigenous Health Equity. Acad Med. 2019;94:512–9.CrossRef
11.
go back to reference Ryan C, Teh R, Moyes S, Wilkinson T, Connolly M, Rolleston A, et al. Quality of prescribing predicts hospitalisation in octogenarians: Life and Living in Advanced Age: A Cohort Study in New Zealand (LiLACS NZ). BMC Geriatr. [In press]. Ryan C, Teh R, Moyes S, Wilkinson T, Connolly M, Rolleston A, et al. Quality of prescribing predicts hospitalisation in octogenarians: Life and Living in Advanced Age: A Cohort Study in New Zealand (LiLACS NZ). BMC Geriatr. [In press].
12.
go back to reference Salmond C, Crampton P, Atkinson J. NZDep 2006 Index of Deprivation. Wellington: Department of Public Health, University of Otago; 2007. Salmond C, Crampton P, Atkinson J. NZDep 2006 Index of Deprivation. Wellington: Department of Public Health, University of Otago; 2007.
13.
go back to reference Essink-Bot M-L, Krabbe PF, Bonsel GJ, Aaronson NK. An empirical comparison of four generic health status measures. Med Care. 1997;35:522–37.CrossRef Essink-Bot M-L, Krabbe PF, Bonsel GJ, Aaronson NK. An empirical comparison of four generic health status measures. Med Care. 1997;35:522–37.CrossRef
14.
go back to reference Teh R, Doughty R, Connolly M, Broad J, Pillai A, Wilkinson T, et al. Agreement between self-reports and medical records of cardiovascular disease in octogenarians. J Clin Epidemiol. 2013;66:1135–43.CrossRef Teh R, Doughty R, Connolly M, Broad J, Pillai A, Wilkinson T, et al. Agreement between self-reports and medical records of cardiovascular disease in octogenarians. J Clin Epidemiol. 2013;66:1135–43.CrossRef
15.
go back to reference World Health Organization Collaborating Centre for Drug Statistics Methodology [Internet]. Oslo: World Health Organization Collaborating Centre for Drug Statistics Methodology; 2019. ATC/DDD Index 2019; [cited 2019 Dec 05]. Available from: http://www.whocc.no/atc_ddd_index/ World Health Organization Collaborating Centre for Drug Statistics Methodology [Internet]. Oslo: World Health Organization Collaborating Centre for Drug Statistics Methodology; 2019. ATC/DDD Index 2019; [cited 2019 Dec 05]. Available from: http://​www.​whocc.​no/​atc_​ddd_​index/​
17.
go back to reference Jackson G, Tobias M. Potentially avoidable hospitalisations in New Zealand, 1989–98. Aust N Z J Public Health. 2001;25:212–21.CrossRef Jackson G, Tobias M. Potentially avoidable hospitalisations in New Zealand, 1989–98. Aust N Z J Public Health. 2001;25:212–21.CrossRef
18.
go back to reference Viera AJ, Garrett JM. Understanding interobserver agreement: the Kappa statistic. Fam Med. 2005;37:360–3.PubMed Viera AJ, Garrett JM. Understanding interobserver agreement: the Kappa statistic. Fam Med. 2005;37:360–3.PubMed
19.
go back to reference Ryan C, O’Mahony D, Byrne S. Application of STOPP and START criteria: interrater reliability among pharmacists. Ann Pharmacother. 2009;43:1239–44.CrossRef Ryan C, O’Mahony D, Byrne S. Application of STOPP and START criteria: interrater reliability among pharmacists. Ann Pharmacother. 2009;43:1239–44.CrossRef
20.
go back to reference Teh RO, Menzies OH, Connolly MJ, Doughty RN, Wilkinson TJ, Pillai A, et al. Patterns of multi-morbidity and prediction of hospitalisation and all-cause mortality in advanced age. Age Ageing. 2018;47:261–8.CrossRef Teh RO, Menzies OH, Connolly MJ, Doughty RN, Wilkinson TJ, Pillai A, et al. Patterns of multi-morbidity and prediction of hospitalisation and all-cause mortality in advanced age. Age Ageing. 2018;47:261–8.CrossRef
21.
go back to reference Teh R, Kerse N, Kepa M, Doughty RN, Moyes S, Wiles J, et al. Self-rated health, health related behaviours and medical conditions of Māori and non-Māori in advanced age: LiLACS NZ. N Z Med J. 2014;127:13–29.PubMed Teh R, Kerse N, Kepa M, Doughty RN, Moyes S, Wiles J, et al. Self-rated health, health related behaviours and medical conditions of Māori and non-Māori in advanced age: LiLACS NZ. N Z Med J. 2014;127:13–29.PubMed
22.
go back to reference Cormack DM, Harris RB, Stanley J. Investigating the Relationship between Socially-Assigned Ethnicity, Racial Discrimination and Health Advantage in New Zealand. PLoS One. 2013;8:e84039.CrossRef Cormack DM, Harris RB, Stanley J. Investigating the Relationship between Socially-Assigned Ethnicity, Racial Discrimination and Health Advantage in New Zealand. PLoS One. 2013;8:e84039.CrossRef
23.
go back to reference Carr J, Robson B, Reid P, Purdie G, Workman P. Heart failure: ethnic disparities in morbidity and mortality in New Zealand. N Z Med J. 2002;115:15–7.PubMed Carr J, Robson B, Reid P, Purdie G, Workman P. Heart failure: ethnic disparities in morbidity and mortality in New Zealand. N Z Med J. 2002;115:15–7.PubMed
24.
go back to reference Curtis E, Harwood M, Riddell T, Robson B, Harris R, Mills C, et al. Access and Society as Determinants of Ischaemic Heart Disease in Indigenous Populations. Hear Lung Circ. 2010;19:316–24.CrossRef Curtis E, Harwood M, Riddell T, Robson B, Harris R, Mills C, et al. Access and Society as Determinants of Ischaemic Heart Disease in Indigenous Populations. Hear Lung Circ. 2010;19:316–24.CrossRef
25.
go back to reference Harris R, Robson B, Curtis E, Purdie G, Cormack D, Reid P. Māori and non-Māori differences in caesarean section rates: a national review. N Z Med J. 2007;120:U2444.PubMed Harris R, Robson B, Curtis E, Purdie G, Cormack D, Reid P. Māori and non-Māori differences in caesarean section rates: a national review. N Z Med J. 2007;120:U2444.PubMed
26.
go back to reference Mills C, Reid P, Vaithianathan R. The cost of child health inequalities in Aotearoa New Zealand: a preliminary scoping study. BMC Public Health. 2012;12:384.CrossRef Mills C, Reid P, Vaithianathan R. The cost of child health inequalities in Aotearoa New Zealand: a preliminary scoping study. BMC Public Health. 2012;12:384.CrossRef
27.
go back to reference Signal L, Martin J, Reid P, Carroll C, Howden-Chapman P, Ormsby VK, et al. Tackling health inequalities: moving theory to action. Int J Equity Health. 2007;6:12.CrossRef Signal L, Martin J, Reid P, Carroll C, Howden-Chapman P, Ormsby VK, et al. Tackling health inequalities: moving theory to action. Int J Equity Health. 2007;6:12.CrossRef
28.
go back to reference Davidson PM, MacIsaac A, Cameron J, Jeremy R, Mahar L, Anderson I. Problems, Solutions and Actions: Addressing Barriers in Acute Hospital Care for Indigenous Australians and New Zealanders. Hear Lung Circ. 2012;21:639–43.CrossRef Davidson PM, MacIsaac A, Cameron J, Jeremy R, Mahar L, Anderson I. Problems, Solutions and Actions: Addressing Barriers in Acute Hospital Care for Indigenous Australians and New Zealanders. Hear Lung Circ. 2012;21:639–43.CrossRef
30.
go back to reference de Jong MR, Van der Elst M, Hartholt KA. Drug-related falls in older patients: implicated drugs, consequences, and possible prevention strategies. Therap Adv Drug Saf. 2013;4:147–54.CrossRef de Jong MR, Van der Elst M, Hartholt KA. Drug-related falls in older patients: implicated drugs, consequences, and possible prevention strategies. Therap Adv Drug Saf. 2013;4:147–54.CrossRef
31.
go back to reference Bolland MJ, Barber PA, Doughty RN, Mason B, Horne A, Ames R, et al. Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. BMJ. 2008;336:262–6.CrossRef Bolland MJ, Barber PA, Doughty RN, Mason B, Horne A, Ames R, et al. Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. BMJ. 2008;336:262–6.CrossRef
32.
go back to reference Reid IR, Bolland MJ, Grey A. Does calcium supplementation increase cardiovascular risk? Clin Endocrinol. 2010;73:689–95.CrossRef Reid IR, Bolland MJ, Grey A. Does calcium supplementation increase cardiovascular risk? Clin Endocrinol. 2010;73:689–95.CrossRef
33.
go back to reference Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887–98.CrossRef Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887–98.CrossRef
34.
go back to reference Shepherd J, Blauw GJ, Murphy MB, Bollen ELEM, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623–30.CrossRef Shepherd J, Blauw GJ, Murphy MB, Bollen ELEM, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623–30.CrossRef
35.
go back to reference Byrne P, Cullinan J, Smith SM. Statins for primary prevention of cardiovascular disease. BMJ. 2019;367:l5674.CrossRef Byrne P, Cullinan J, Smith SM. Statins for primary prevention of cardiovascular disease. BMJ. 2019;367:l5674.CrossRef
36.
go back to reference Dyall L, Kepa M, Hayman K, Teh R, Moyes S, Broad JB, et al. Engagement and recruitment of Māori and non-Māori people of advanced age to LiLACS NZ. Aust NZ J Publ Heal. 2013;37:124–31.CrossRef Dyall L, Kepa M, Hayman K, Teh R, Moyes S, Broad JB, et al. Engagement and recruitment of Māori and non-Māori people of advanced age to LiLACS NZ. Aust NZ J Publ Heal. 2013;37:124–31.CrossRef
37.
go back to reference Kerse N, Teh R, Moyes SA, Broad J, Rolleston A, Gott M, et al. Cohort Profile: Te Puawaitanga o Nga Tapuwae Kia Ora Tonu, Life and Living in Advanced Age: a Cohort Study in New Zealand (LiLACS NZ). Int J Epidemiol. 2015;44:1823–32.CrossRef Kerse N, Teh R, Moyes SA, Broad J, Rolleston A, Gott M, et al. Cohort Profile: Te Puawaitanga o Nga Tapuwae Kia Ora Tonu, Life and Living in Advanced Age: a Cohort Study in New Zealand (LiLACS NZ). Int J Epidemiol. 2015;44:1823–32.CrossRef
38.
go back to reference Barenholtz Levy H, Marcus EL. Potentially inappropriate medications in older adults: why the revised criteria matter. Ann Pharmacother. 2016;50:599–603.CrossRef Barenholtz Levy H, Marcus EL. Potentially inappropriate medications in older adults: why the revised criteria matter. Ann Pharmacother. 2016;50:599–603.CrossRef
39.
go back to reference Frank KA. Impact of a confounding variable on a regression coefficient. Sociol Method Res. 2000;29:147–9.CrossRef Frank KA. Impact of a confounding variable on a regression coefficient. Sociol Method Res. 2000;29:147–9.CrossRef
Metadata
Title
Does potentially inappropriate prescribing predict an increased risk of admission to hospital and mortality? A longitudinal study of the ‘oldest old’
Authors
Karen Cardwell
Ngaire Kerse
Carmel M. Hughes
Ruth Teh
Simon A. Moyes
Oliver Menzies
Anna Rolleston
Joanna B. Broad
Cristín Ryan
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Geriatrics / Issue 1/2020
Electronic ISSN: 1471-2318
DOI
https://doi.org/10.1186/s12877-020-1432-4

Other articles of this Issue 1/2020

BMC Geriatrics 1/2020 Go to the issue